Who are Nrxpharma's investors?

Nrxpharma's investors include Kinled Holding.

How much funding has Nrxpharma raised?

Nrxpharma has disclosed $6M raised across 2 rounds.

Where is Nrxpharma headquartered?

Nrxpharma is headquartered in Wilmington, US.

Nrxpharma

Wilmington, US · Founded 2017 · 1 known investors

Find your way into Nrxpharma

1,501 people in our graph share verified history with the Nrxpharma team — schools, employers, funds. One of them is your warm intro.

Diana Berishaunlockedknows Dennis K. McBride · together at Georgetown (overlapped)

×4knows the team · via Harvard Business School

×2knows the team · via The London School of Economics and Political Science (LSE)

knows the team · via Georgetown

knows the team · via Cornell Johnson Graduate School of Management

×2knows the team · via Defense Advanced Research Projects Agency (DARPA)

NRx Pharmaceuticals develops medicines for people with unmet medical needs, focused on making untreatable diseases treatable. It operates in the pharmaceutical and biotech industry.

Biotech Digital Health Healthtech Mental Health

Founders & leadership

Nrxpharma was founded in 2017 by Jonathan Javitt, Daniel C. Javitt, Jonathan C. Javitt, M.D., M.P.H., and Prof. Daniel C. Javitt, M.D., Ph.D..

Jonathan JavittFounder, Chairman & CEO

Daniel C. JavittCo-founder & Chair, Scientific Advisory Board

Jonathan C. Javitt, M.D., M.P.H.inFounder, Chairman & Chief Scientist; Co-CEO HOPE TherapeuticsJavitt founded NeuroRx, Inc., which he led as CEO from 2015 to 2021, and previously co-founded Telcare, Inc., where he served as vice chairman, alongside a long tenure as a venture partner at Pontifax, LP. He is an adjunct professor of ophthalmology at Johns Hopkins Medicine and a senior fellow at the Potomac Institute for Policy Studies, and served as the company's chief scientist and a director before taking on his current role.

Prof. Daniel C. Javitt, M.D., Ph.D.Co-founder & Chair, Scientific Advisory Board

Michael AbramsChief Financial Officer

Kim BennettChief Investment Officer

Richard AckermanChairman, President and Chief Executive Officer

Lori B. WittmanChief Financial Officer and Director

Rick PanicucciChief Manufacturing Officer

Dennis K. McBride inChief Strategy OfficerDennis McBride has over 45 years of experience applying scientific and engineering methods to complex technical analysis and decision support across litigation, government, medicine, and defense. A retired U.S. Navy Captain with advanced degrees in Human Factors Engineering and Modeling & Simulation, he previously held senior roles at DARPA, the Pentagon, and multiple defense research laboratories, and served as a professor in engineering and medicine.

Glenn D. TysoninChief Commercial Officer

Joshua BrownChief Medical Innovation Officer

Investors · 1

Kinled HoldingHong Kongvia Patrick Aisher · inferred

Reported raises · per SEC filings

Form D private placements

$6M disclosed across 2 rounds · 2017–2025

▶$3.5MraisedMar 2025 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Patrick FlynnDirector
Michael AbramsExecutive Officer
Michael TaylorDirector
Jonathan JavittExecutive Officer, Director
Chaim HurvitzDirector
Dennis McBrideDirector

Offering amount: $3.5M
Amount sold: $3.5M
Sales commissions: $245K
Placement agents: D. Boral Capital
First sale: Jan 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2.5MraisedNov 2017 · 1 investors · Commercial

Rule 506(b)

Officers, directors & promoters on the filing

Kim BennettExecutive Officer
Michael FongDirector
Richard AckermanExecutive Officer, Director
Lori B. WittmanExecutive Officer, Director
Troy T. TaylorDirector
Stuart F. KoenigDirector
Albert G. RexDirector
Richard BardoffDirector

Offering amount: $2.8M
Amount sold: $2.5M
Minimum investment: $25K
First sale: Sep 2017
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Seeking Alpha33 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

Robinhood32 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Companies competing with Nrxpharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Nrxpharma do?: NRx Pharmaceuticals develops medicines for people with unmet medical needs, focused on making untreatable diseases treatable. It operates in the pharmaceutical and biotech industry.
Who founded Nrxpharma?: Nrxpharma was founded by Jonathan Javitt, Daniel C. Javitt, Jonathan C. Javitt, M.D., M.P.H., Prof. Daniel C. Javitt, M.D., Ph.D. in 2017.
Who are Nrxpharma's investors?: Nrxpharma's investors include Kinled Holding.
How much funding has Nrxpharma raised?: Nrxpharma has disclosed $6M raised across 2 rounds.
Where is Nrxpharma headquartered?: Nrxpharma is headquartered in Wilmington, US.